The global demand for Teriflunomide Market is presumed to reach the valuation of nearly USD XX MN by 2026 from USD XX MN in 2019 with a CAGR of XX% under the study period of 2020 - 2026.
Teriflunomide is the active metabolite of leflunomide used to treat multiple sclerosis. It is an immunomodulatory drug that inhibits the synthesis of pyrimidine de novo by blocking the enzyme dihydroorotate dehydrogenase. It works by inhibits rapidly dividing cells, including activated T cells, which are thought to drive the disease process in multiple sclerosis. It is sold under the brand name Aubagio.
The rising burden of multiple sclerosis, cancer, and autoimmune disease, together with growing FDA, drives the growth of the global teriflunomide market. Teriflunomide is majorly used in the treatment of relapsing and remitting forms of multiple sclerosis. Teriflunomide is a potential candidate for multiple sclerosis treatment. In recent years, the FDA has approved the number of companies for teriflunomide. As per findings from a National MS Society study, it is estimated that nearly 1 million people in the United States live with multiple sclerosis, and 2.3 million people live with MS globally. About 200 new cases are diagnosed each week in the United States. The role of teriflunomide among the growing number of treatment options will further amplify the demand. It is promising for other diseases like cancer and autoimmune disorders. Looking into the trends, teriflunomide is projected to foresee tremendous growth in the coming years.
The report covers Porter’s Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level.
Additionally, these tools also give inclusive assessment of each application/product segment in the global market of teriflunomide.
The entire Teriflunomide market has been sub-categorized into type, application. The report provides an analysis of these subsets with respect to the geographical segmentation. This research study will keep marketer informed and helps to identify the target demographics for a product or service.
- Cancer Treatment
- Multiple sclerosis
This section covers regional segmentation which accentuates on current and future demand for teriflunomide market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.
Global Teriflunomide Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the teriflunomide market include Sanofi Aventis, Genzyme Corporation, Amneal Pharmaceuticals NY LC, Glenmark Pharmaceuticals, Msn Laboratories Private Limited, Alembic Pharmaceuticals, Natco. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
This market research report has been produced by gathering information on the basis of primary and secondary research. Secondary research has been done by using various sources which include (but not limited to) Company Websites, Paid Data Sources, Technical Journals, Financial Reports, SEC Filings, and other different industry publications.
If specific information is required which is not currently within the scope of the report, it can be provided as a part of customization.